2-((((9H-Fluoren-9-YL)methoxy)carbonyl)(methyl)amino)acetic acid hydrate | 77128-70-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - FMOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 2-((((9H-Fluoren-9-YL)methoxy)carbonyl)(methyl)amino)acetic acid hydrate
• 英文别名: 2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid;hydrate
• CAS: 77128-70-2
• 化学式: C18H19NO5
• 分子量: 329.3
• InChiKey: CUJSWOOWOONPRH-UHFFFAOYSA-N

物化性质

• 熔点：
  117.0 to 121.0 °C
• 沸点：
  512.8±29.0 °C(Predicted)
• 密度：
  1.292±0.06 g/cm3(Predicted)
• 溶解度：
  溶于DMF

计算性质

• 辛醇/水分配系数(LogP)：
  2.13
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  2922509090
• 危险品运输编号：
  NONH for all modes of transport
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

制备方法与用途

用途

芴甲氧羰酰基肌氨酸是固相肽合成（SPPS）中常用的保护氨基酸之一。在肽链合成过程中，通过保护氨基酸的氨基和羧基，可以有效避免不必要的化学反应发生。

文献信息

• BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2
  申请人：BicycleTx Limited

  公开号：US20190184025A1

  公开（公告）日：2019-06-20

  The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

  本发明涉及与非芳香分子支架共价结合的多肽，使得两个或更多肽环被夹在连接点到支架之间。具体而言，本发明描述了高亲和力结合Eph受体酪氨酸激酶A2（EphA2）的肽。本发明还包括包含所述肽的药物结合物，与一个或多个效应物和/或功能基团结合，以及包含所述肽配体和药物结合物的制药组合物，以及在预防、抑制或治疗由过度表达EphA2在患病组织（如肿瘤）中的疾病或障碍中使用所述肽配体和药物结合物。
• METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US20220411462A1

  公开（公告）日：2022-12-29

  The present invention provides methods for producing peptide compounds. The inventors have found that a cyclic peptide compound can be produced efficiently by linking the N-terminal amino acid residue and the C-terminal amino acid residue of a peptide compound in a solvent containing one or more selected from the group consisting of water-immiscible solvents, water-soluble alkyl nitriles, and water-soluble ethers.

  本发明提供了生产肽化合物的方法。发明人发现，在含有水不相溶溶剂、水溶性烷基硝基化合物和水溶性醚类化合物中，通过将肽化合物的N-末端氨基酸残基和C-末端氨基酸残基连接起来，可以高效地生产环肽化合物。
• BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2
  申请人：BicycleTx Limited

  公开号：EP4053145A1

  公开（公告）日：2022-09-07

  The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

  本发明涉及与非芳香族分子支架共价结合的多肽，其与支架的连接点之间有两个或多个肽环。特别是，本发明描述的肽是 Eph 受体酪氨酸激酶 A2（EphA2）的高亲和力结合剂。本发明还包括包含所述多肽、与一个或多个效应基团和/或功能基团共轭的药物共轭物，包含所述多肽配体和药物共轭物的药物组合物，以及所述多肽配体和药物共轭物在预防、抑制或治疗以病变组织（如肿瘤）中EphA2过度表达为特征的疾病或紊乱中的用途。
• MASP INHIBITORY COMPOUNDS AND USES THEREOF
  申请人：Bayer Aktiengesellschaft

  公开号：US20210246166A1

  公开（公告）日：2021-08-12

  The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.